English

ALBANY MOLECULAR RESEARCH INC

EDGAR

AMRI Filing amendment (SC 13D/A) · filed 2017-09-05

211 filing records in this dataset, filed from 1999-03-31 to 2017-09-05. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

173 million USD

2017 Q2 · USD

Exact inputs and evidence

Revenue: 172932000 USD Source

Operating margin

-0.9%

2017 Q2 · %

Exact inputs and evidence

Operating Income: -1556000 USD Source
Revenue: 172932000 USD Source

Operating cash flow

14.9 million USD

2017 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 8520000 USD Source
Operating Cash Flow: -6410000 USD Source

Free cash flow

8.39 million USD

2017 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: 8520000 USD Source
Operating Cash Flow: -6410000 USD Source
Capital Expenditure: 10486000 USD Source
Capital Expenditure: 3949000 USD Source

Cash and cash equivalents: 42.2 million USD 2017-06-30 Source
Exact value

42227000 USD
Long-term debt including current maturities: 635 million USD 2017-06-30 Source
Exact value

635160000 USD
Shares outstanding: 48.5 million shares 2016-12-31 Source
Exact value

48465000 shares

Reported share-count change

17.83% · 7.34 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

41130000 shares · 2015-12-31· Source
48465000 shares · 2016-12-31· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

681 million USD

2016-07-01 – 2017-06-30

Exact inputs and evidence

Revenue: 152738000 USD · 2016-07-01 – 2016-09-30 Source
Revenue: 191323000 USD · 2016-10-01 – 2016-12-31 Source
Revenue: 163822000 USD · 2017-01-01 – 2017-03-31 Source
Revenue: 172932000 USD · 2017-04-01 – 2017-06-30 Source

Net income

-59.8 million USD

2016-07-01 – 2017-06-30

Exact inputs and evidence

Net income: -23425000 USD · 2016-07-01 – 2016-09-30 Source
Net income: -15412000 USD · 2016-10-01 – 2016-12-31 Source
Net income: -10692000 USD · 2017-01-01 – 2017-03-31 Source
Net income: -10247000 USD · 2017-04-01 – 2017-06-30 Source

Operating cash flow

19.9 million USD

2016-07-01 – 2017-06-30

Exact inputs and evidence

Operating cash flow: 5228000 USD · 2016-01-01 – 2016-09-30 Source
Operating cash flow: 15241000 USD · 2016-01-01 – 2016-06-30 Source
Operating cash flow: 26635000 USD · 2016-01-01 – 2016-12-31 Source
Operating cash flow: 5228000 USD · 2016-01-01 – 2016-09-30 Source
Operating cash flow: -6410000 USD · 2017-01-01 – 2017-03-31 Source
Operating cash flow: 8520000 USD · 2017-01-01 – 2017-06-30 Source
Operating cash flow: -6410000 USD · 2017-01-01 – 2017-03-31 Source

Capital expenditure

36.9 million USD

2016-07-01 – 2017-06-30

Exact inputs and evidence

Capital expenditure: 37952000 USD · 2016-01-01 – 2016-09-30 Source
Capital expenditure: 24966000 USD · 2016-01-01 – 2016-06-30 Source
Capital expenditure: 51428000 USD · 2016-01-01 – 2016-12-31 Source
Capital expenditure: 37952000 USD · 2016-01-01 – 2016-09-30 Source
Capital expenditure: 3949000 USD · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 10486000 USD · 2017-01-01 – 2017-06-30 Source
Capital expenditure: 3949000 USD · 2017-01-01 – 2017-03-31 Source

Free cash flow

-17 million USD

2016-07-01 – 2017-06-30

Exact inputs and evidence

Operating cash flow: 5228000 USD · 2016-01-01 – 2016-09-30 Source
Operating cash flow: 15241000 USD · 2016-01-01 – 2016-06-30 Source
Operating cash flow: 26635000 USD · 2016-01-01 – 2016-12-31 Source
Operating cash flow: 5228000 USD · 2016-01-01 – 2016-09-30 Source
Operating cash flow: -6410000 USD · 2017-01-01 – 2017-03-31 Source
Operating cash flow: 8520000 USD · 2017-01-01 – 2017-06-30 Source
Operating cash flow: -6410000 USD · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 37952000 USD · 2016-01-01 – 2016-09-30 Source
Capital expenditure: 24966000 USD · 2016-01-01 – 2016-06-30 Source
Capital expenditure: 51428000 USD · 2016-01-01 – 2016-12-31 Source
Capital expenditure: 37952000 USD · 2016-01-01 – 2016-09-30 Source
Capital expenditure: 3949000 USD · 2017-01-01 – 2017-03-31 Source
Capital expenditure: 10486000 USD · 2017-01-01 – 2017-06-30 Source
Capital expenditure: 3949000 USD · 2017-01-01 – 2017-03-31 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2017-09-05.

Financial data available through: 2016-12-31.

Coverage by financial measure

Revenue: 11 of 11 periods available· newest 2016-12-31
Operating income: 11 of 11 periods available· newest 2016-12-31
Net income: 11 of 11 periods available· newest 2016-12-31
Operating cash flow: 11 of 11 periods available· newest 2016-12-31
Capital expenditure: 11 of 11 periods available· newest 2016-12-31
Total assets: 11 of 11 periods available· newest 2016-12-31
Total liabilities: 11 of 11 periods available· newest 2016-12-31
Current assets: 11 of 11 periods available· newest 2016-12-31
Current liabilities: 11 of 11 periods available· newest 2016-12-31
Cash and cash equivalents: 11 of 11 periods available· newest 2016-12-31
Long-term debt including current maturities: 6 of 11 periods available· newest 2016-12-31
Shares outstanding: 2 of 11 periods available· newest 2016-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+41.8%

Prior period

USD 402.36 million

2015-01-01 – 2015-12-31
Current period

USD 570.45 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

570450000 − 402356000 = 168094000 USD

402356000 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
570450000 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · ALBANY MOLECULAR RESEARCH INC · 2016-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Year-over-year change in Revenue: 168094000 USD Concept: fundies:Revenue Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 570450000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#315889 Filing: 000114420417015129 Input fundies:Revenue: 402356000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#316018 Filing: 000114420417015129
The citation records this snapshot. The page link may show a newer release later.
Net income
−USD 67.87 million

Prior period

−USD 2.3 million

2015-01-01 – 2015-12-31
Current period

−USD 70.17 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

-70171000 − -2301000 = -67870000 USD

-2301000 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
-70171000 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ALBANY MOLECULAR RESEARCH INC · 2016-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Year-over-year change in Net income: -67870000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -70171000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#319022 Filing: 000114420417015129 Input fundies:NetIncome: -2301000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#319162 Filing: 000114420417015129
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-32.8%

Prior period

USD 39.63 million

2015-01-01 – 2015-12-31
Current period

USD 26.64 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

26635000 − 39628000 = -12993000 USD

39628000 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
26635000 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ALBANY MOLECULAR RESEARCH INC · 2016-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Year-over-year change in Operating cash flow: -12993000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 26635000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1794669 Filing: 000114420417015129 Input fundies:OperatingCashFlow: 39628000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1794908 Filing: 000114420417015129
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+133.3%

Prior period

USD 22.04 million

2015-01-01 – 2015-12-31
Current period

USD 51.43 million

2016-01-01 – 2016-12-31

Exact inputs and evidence

51428000 − 22041000 = 29387000 USD

22041000 USD · 2015-01-01 – 2015-12-31
Inspect prior input Prior source
51428000 USD · 2016-01-01 – 2016-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ALBANY MOLECULAR RESEARCH INC · 2016-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Year-over-year change in Capital expenditure: 29387000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 51428000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1795997 Filing: 000114420417015129 Input fundies:CapitalExpenditure: 22041000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1796196 Filing: 000114420417015129
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2016 2016-01-01 – 2016-12-31

Revenue USD 570.45 million 100% of revenue
Operating costs Derived USD 589.21 million 103% of revenue
Operating income −USD 18.76 million −3.3% of revenue
Tax, interest and other Derived USD 51.41 million 9% of revenue
Net income −USD 70.17 million −12% of revenue

Cash

Operating cash flow USD 26.64 million 4.7% of revenue
Capital expenditure USD 51.43 million 9% of revenue
Free cash flow Derived −USD 24.79 million −4.3% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2007 94%
2008 89%
2009 Operating loss: operating costs were 111% of revenue.
2010 Operating loss: operating costs were 136% of revenue.
2011 Operating loss: operating costs were 117% of revenue.
2012 Net loss: net income was −1.9% of revenue.
2013 92%
2014 Net loss: net income was −1.2% of revenue.
2015 Net loss: net income was −0.6% of revenue.
2016 Operating loss: operating costs were 103% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2007 2007-01-01 – 2007-12-31	192511000	181160000 Derived	11351000	2415000 Derived	8936000	13920000 Derived	Source 2007-01-01 – 2007-12-31: 192511000 USD Inspect Revenue Open source 2007-01-01 – 2007-12-31: 11351000 USD Inspect Operating Income Open source 2007-01-01 – 2007-12-31: 8936000 USD Inspect Net Income Open source 2007-01-01 – 2007-12-31: 31667000 USD Inspect Operating Cash Flow Open source 2007-01-01 – 2007-12-31: 17747000 USD Inspect Capital Expenditure Open source
2008 2008-01-01 – 2008-12-31	229260000	203299000 Derived	25961000	5401000 Derived	20560000	2602000 Derived	Source 2008-01-01 – 2008-12-31: 229260000 USD Inspect Revenue Open source 2008-01-01 – 2008-12-31: 25961000 USD Inspect Operating Income Open source 2008-01-01 – 2008-12-31: 20560000 USD Inspect Net Income Open source 2008-01-01 – 2008-12-31: 26540000 USD Inspect Operating Cash Flow Open source 2008-01-01 – 2008-12-31: 23938000 USD Inspect Capital Expenditure Open source
2009 2009-01-01 – 2009-12-31	196417000	218145000 Derived	-21728000	-5033000 Derived	-16695000	23914000 Derived	Source 2009-01-01 – 2009-12-31: 196417000 USD Inspect Revenue Open source 2009-01-01 – 2009-12-31: -21728000 USD Inspect Operating Income Open source 2009-01-01 – 2009-12-31: -16695000 USD Inspect Net Income Open source 2009-01-01 – 2009-12-31: 39086000 USD Inspect Operating Cash Flow Open source 2009-01-01 – 2009-12-31: 15172000 USD Inspect Capital Expenditure Open source
2010 2010-01-01 – 2010-12-31	198066000	270061000 Derived	-71995000	-9124000 Derived	-62871000	-12949000 Derived	Source 2010-01-01 – 2010-12-31: 198066000 USD Inspect Revenue Open source 2010-01-01 – 2010-12-31: -71995000 USD Inspect Operating Income Open source 2010-01-01 – 2010-12-31: -62871000 USD Inspect Net Income Open source 2010-01-01 – 2010-12-31: -1321000 USD Inspect Operating Cash Flow Open source 2010-01-01 – 2010-12-31: 11628000 USD Inspect Capital Expenditure Open source
2011 2011-01-01 – 2011-12-31	207645000	243777000 Derived	-36132000	-3836000 Derived	-32296000	-12318000 Derived	Source 2011-01-01 – 2011-12-31: 207645000 USD Inspect Revenue Open source 2011-01-01 – 2011-12-31: -36132000 USD Inspect Operating Income Open source 2011-01-01 – 2011-12-31: -32296000 USD Inspect Net Income Open source 2011-01-01 – 2011-12-31: -1481000 USD Inspect Operating Cash Flow Open source 2011-01-01 – 2011-12-31: 10837000 USD Inspect Capital Expenditure Open source
2012 2012-01-01 – 2012-12-31	226686000	225983000 Derived	703000	4964000 Derived	-4261000	5447000 Derived	Source 2012-01-01 – 2012-12-31: 226686000 USD Inspect Revenue Open source 2012-01-01 – 2012-12-31: 703000 USD Inspect Operating Income Open source 2012-01-01 – 2012-12-31: -4261000 USD Inspect Net Income Open source 2012-01-01 – 2012-12-31: 15337000 USD Inspect Operating Cash Flow Open source 2012-01-01 – 2012-12-31: 9890000 USD Inspect Capital Expenditure Open source
2013 2013-01-01 – 2013-12-31	246575000	226400000 Derived	20175000	8407000 Derived	11768000	17041000 Derived	Source 2013-01-01 – 2013-12-31: 246575000 USD Inspect Revenue Open source 2013-01-01 – 2013-12-31: 20175000 USD Inspect Operating Income Open source 2013-01-01 – 2013-12-31: 11768000 USD Inspect Net Income Open source 2013-01-01 – 2013-12-31: 28176000 USD Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 11135000 USD Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	276571000	270847000 Derived	5724000	9002000 Derived	-3278000	-15284000 Derived	Source 2014-01-01 – 2014-12-31: 276571000 USD Inspect Revenue Open source 2014-01-01 – 2014-12-31: 5724000 USD Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -3278000 USD Inspect Net Income Open source 2014-01-01 – 2014-12-31: 1905000 USD Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 17189000 USD Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	402356000	388707000 Derived	13649000	15950000 Derived	-2301000	17587000 Derived	Source 2015-01-01 – 2015-12-31: 402356000 USD Inspect Revenue Open source 2015-01-01 – 2015-12-31: 13649000 USD Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -2301000 USD Inspect Net Income Open source 2015-01-01 – 2015-12-31: 39628000 USD Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 22041000 USD Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	570450000	589209000 Derived	-18759000	51412000 Derived	-70171000	-24793000 Derived	Source 2016-01-01 – 2016-12-31: 570450000 USD Inspect Revenue Open source 2016-01-01 – 2016-12-31: -18759000 USD Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -70171000 USD Inspect Net Income Open source 2016-01-01 – 2016-12-31: 26635000 USD Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 51428000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 570.5M 2016

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20072007-12-31	Revenue	192511000	Revenue: 192511000 Open source
20082008-12-31	Revenue	229260000	Revenue: 229260000 Open source
20092009-12-31	Revenue	196417000	Revenue: 196417000 Open source
20102010-12-31	Revenue	198066000	Revenue: 198066000 Open source
20112011-12-31	Revenue	207645000	Revenue: 207645000 Open source
20122012-12-31	Revenue	226686000	Revenue: 226686000 Open source
20132013-12-31	Revenue	246575000	Revenue: 246575000 Open source
20142014-12-31	Revenue	276571000	Revenue: 276571000 Open source
20152015-12-31	Revenue	402356000	Revenue: 402356000 Open source
20162016-12-31	Revenue	570450000	Revenue: 570450000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

41.8% 2016

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20072007-12-31	Year over year	7.1%	Revenue: 192511000 Open source Revenue: 179807000 Open source
20082008-12-31	Year over year	19.1%	Revenue: 229260000 Open source Revenue: 192511000 Open source
20092009-12-31	Year over year	-14.3%	Revenue: 196417000 Open source Revenue: 229260000 Open source
20102010-12-31	Year over year	0.8%	Revenue: 198066000 Open source Revenue: 196417000 Open source
20112011-12-31	Year over year	4.8%	Revenue: 207645000 Open source Revenue: 198066000 Open source
20122012-12-31	Year over year	9.2%	Revenue: 226686000 Open source Revenue: 207645000 Open source
20132013-12-31	Year over year	8.8%	Revenue: 246575000 Open source Revenue: 226686000 Open source
20142014-12-31	Year over year	12.2%	Revenue: 276571000 Open source Revenue: 246575000 Open source
20152015-12-31	Year over year	45.5%	Revenue: 402356000 Open source Revenue: 276571000 Open source
20162016-12-31	Year over year	41.8%	Revenue: 570450000 Open source Revenue: 402356000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -3.3% 2016

Net margin -12.3% 2016

Free cash flow margin -4.3% 2016

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20072007-12-31	Operating margin	5.9%	Operating Income: 11351000 Open source Revenue: 192511000 Open source
20082008-12-31	Operating margin	11.3%	Operating Income: 25961000 Open source Revenue: 229260000 Open source
20092009-12-31	Operating margin	-11.1%	Operating Income: -21728000 Open source Revenue: 196417000 Open source
20102010-12-31	Operating margin	-36.3%	Operating Income: -71995000 Open source Revenue: 198066000 Open source
20112011-12-31	Operating margin	-17.4%	Operating Income: -36132000 Open source Revenue: 207645000 Open source
20122012-12-31	Operating margin	0.3%	Operating Income: 703000 Open source Revenue: 226686000 Open source
20132013-12-31	Operating margin	8.2%	Operating Income: 20175000 Open source Revenue: 246575000 Open source
20142014-12-31	Operating margin	2.1%	Operating Income: 5724000 Open source Revenue: 276571000 Open source
20152015-12-31	Operating margin	3.4%	Operating Income: 13649000 Open source Revenue: 402356000 Open source
20162016-12-31	Operating margin	-3.3%	Operating Income: -18759000 Open source Revenue: 570450000 Open source
20072007-12-31	Net margin	4.6%	Net Income: 8936000 Open source Revenue: 192511000 Open source
20082008-12-31	Net margin	9%	Net Income: 20560000 Open source Revenue: 229260000 Open source
20092009-12-31	Net margin	-8.5%	Net Income: -16695000 Open source Revenue: 196417000 Open source
20102010-12-31	Net margin	-31.7%	Net Income: -62871000 Open source Revenue: 198066000 Open source
20112011-12-31	Net margin	-15.6%	Net Income: -32296000 Open source Revenue: 207645000 Open source
20122012-12-31	Net margin	-1.9%	Net Income: -4261000 Open source Revenue: 226686000 Open source
20132013-12-31	Net margin	4.8%	Net Income: 11768000 Open source Revenue: 246575000 Open source
20142014-12-31	Net margin	-1.2%	Net Income: -3278000 Open source Revenue: 276571000 Open source
20152015-12-31	Net margin	-0.6%	Net Income: -2301000 Open source Revenue: 402356000 Open source
20162016-12-31	Net margin	-12.3%	Net Income: -70171000 Open source Revenue: 570450000 Open source
20072007-12-31	Free cash flow margin	7.2%	Revenue: 192511000 Open source Operating Cash Flow: 31667000 Open source Capital Expenditure: 17747000 Open source
20082008-12-31	Free cash flow margin	1.1%	Revenue: 229260000 Open source Operating Cash Flow: 26540000 Open source Capital Expenditure: 23938000 Open source
20092009-12-31	Free cash flow margin	12.2%	Revenue: 196417000 Open source Operating Cash Flow: 39086000 Open source Capital Expenditure: 15172000 Open source
20102010-12-31	Free cash flow margin	-6.5%	Revenue: 198066000 Open source Operating Cash Flow: -1321000 Open source Capital Expenditure: 11628000 Open source
20112011-12-31	Free cash flow margin	-5.9%	Revenue: 207645000 Open source Operating Cash Flow: -1481000 Open source Capital Expenditure: 10837000 Open source
20122012-12-31	Free cash flow margin	2.4%	Revenue: 226686000 Open source Operating Cash Flow: 15337000 Open source Capital Expenditure: 9890000 Open source
20132013-12-31	Free cash flow margin	6.9%	Revenue: 246575000 Open source Operating Cash Flow: 28176000 Open source Capital Expenditure: 11135000 Open source
20142014-12-31	Free cash flow margin	-5.5%	Revenue: 276571000 Open source Operating Cash Flow: 1905000 Open source Capital Expenditure: 17189000 Open source
20152015-12-31	Free cash flow margin	4.4%	Revenue: 402356000 Open source Operating Cash Flow: 39628000 Open source Capital Expenditure: 22041000 Open source
20162016-12-31	Free cash flow margin	-4.3%	Revenue: 570450000 Open source Operating Cash Flow: 26635000 Open source Capital Expenditure: 51428000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 26.6M 2016

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20072007-12-31	Operating cash flow	31667000	Operating Cash Flow: 31667000 Open source
20082008-12-31	Operating cash flow	26540000	Operating Cash Flow: 26540000 Open source
20092009-12-31	Operating cash flow	39086000	Operating Cash Flow: 39086000 Open source
20102010-12-31	Operating cash flow	-1321000	Operating Cash Flow: -1321000 Open source
20112011-12-31	Operating cash flow	-1481000	Operating Cash Flow: -1481000 Open source
20122012-12-31	Operating cash flow	15337000	Operating Cash Flow: 15337000 Open source
20132013-12-31	Operating cash flow	28176000	Operating Cash Flow: 28176000 Open source
20142014-12-31	Operating cash flow	1905000	Operating Cash Flow: 1905000 Open source
20152015-12-31	Operating cash flow	39628000	Operating Cash Flow: 39628000 Open source
20162016-12-31	Operating cash flow	26635000	Operating Cash Flow: 26635000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -24.8M 2016

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20072007-12-31	Free cash flow	13920000	Operating Cash Flow: 31667000 Open source Capital Expenditure: 17747000 Open source
20082008-12-31	Free cash flow	2602000	Operating Cash Flow: 26540000 Open source Capital Expenditure: 23938000 Open source
20092009-12-31	Free cash flow	23914000	Operating Cash Flow: 39086000 Open source Capital Expenditure: 15172000 Open source
20102010-12-31	Free cash flow	-12949000	Operating Cash Flow: -1321000 Open source Capital Expenditure: 11628000 Open source
20112011-12-31	Free cash flow	-12318000	Operating Cash Flow: -1481000 Open source Capital Expenditure: 10837000 Open source
20122012-12-31	Free cash flow	5447000	Operating Cash Flow: 15337000 Open source Capital Expenditure: 9890000 Open source
20132013-12-31	Free cash flow	17041000	Operating Cash Flow: 28176000 Open source Capital Expenditure: 11135000 Open source
20142014-12-31	Free cash flow	-15284000	Operating Cash Flow: 1905000 Open source Capital Expenditure: 17189000 Open source
20152015-12-31	Free cash flow	17587000	Operating Cash Flow: 39628000 Open source Capital Expenditure: 22041000 Open source
20162016-12-31	Free cash flow	-24793000	Operating Cash Flow: 26635000 Open source Capital Expenditure: 51428000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

75.3% 2016

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20072007-12-31	Liabilities / assets	13.5%	Total Liabilities: 52086000 Open source Total Assets: 386654000 Open source
20082008-12-31	Liabilities / assets	16.4%	Total Liabilities: 64004000 Open source Total Assets: 390684000 Open source
20092009-12-31	Liabilities / assets	15.8%	Total Liabilities: 59079000 Open source Total Assets: 373692000 Open source
20102010-12-31	Liabilities / assets	25%	Total Liabilities: 81363000 Open source Total Assets: 325106000 Open source
20112011-12-31	Liabilities / assets	21.5%	Total Liabilities: 56633000 Open source Total Assets: 263067000 Open source
20122012-12-31	Liabilities / assets	21.6%	Total Liabilities: 56721000 Open source Total Assets: 262862000 Open source
20132013-12-31	Liabilities / assets	46.5%	Total Liabilities: 204511000 Open source Total Assets: 440184000 Open source
20142014-12-31	Liabilities / assets	53.1%	Total Liabilities: 274046000 Open source Total Assets: 515868000 Open source
20152015-12-31	Liabilities / assets	66.8%	Total Liabilities: 578344000 Open source Total Assets: 865567000 Open source
20162016-12-31	Liabilities / assets	75.3%	Total Liabilities: 910666000 Open source Total Assets: 1209648000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

2.24× 2016

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20072007-12-31	Current assets / current liabilities	4.82×	Current Assets: 175260000 Open source Current Liabilities: 36369000 Open source
20082008-12-31	Current assets / current liabilities	5.16×	Current Assets: 174515000 Open source Current Liabilities: 33822000 Open source
20092009-12-31	Current assets / current liabilities	5.87×	Current Assets: 180464000 Open source Current Liabilities: 30734000 Open source
20102010-12-31	Current assets / current liabilities	2.45×	Current Assets: 134046000 Open source Current Liabilities: 54637000 Open source
20112011-12-31	Current assets / current liabilities	2.65×	Current Assets: 100560000 Open source Current Liabilities: 37976000 Open source
20122012-12-31	Current assets / current liabilities	3.15×	Current Assets: 113424000 Open source Current Liabilities: 35986000 Open source
20132013-12-31	Current assets / current liabilities	5.71×	Current Assets: 279019000 Open source Current Liabilities: 48849000 Open source
20142014-12-31	Current assets / current liabilities	3.87×	Current Assets: 188541000 Open source Current Liabilities: 48690000 Open source
20152015-12-31	Current assets / current liabilities	2.83×	Current Assets: 280245000 Open source Current Liabilities: 99096000 Open source
20162016-12-31	Current assets / current liabilities	2.24×	Current Assets: 392911000 Open source Current Liabilities: 175518000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2007 2007-01-01 – 2007-12-31	USD 8.94 million Exact value Exact value: 8936000 USD 2007-01-01 – 2007-12-31: 8936000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALBANY MOLECULAR RESEARCH INC · 2007-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Net Income: 8936000 USD Concept: fundies:NetIncome Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ANetIncome&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:NetIncome: 8936000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/0001144204-10-013181.txt#15455 The citation records this snapshot. The page link may show a newer release later.	USD 31.67 million Exact value Exact value: 31667000 USD 2007-01-01 – 2007-12-31: 31667000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALBANY MOLECULAR RESEARCH INC · 2007-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Operating Cash Flow: 31667000 USD Concept: fundies:OperatingCashFlow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3AOperatingCashFlow&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 31667000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/0001144204-10-013181.txt#15907 The citation records this snapshot. The page link may show a newer release later.	USD 17.75 million Exact value Exact value: 17747000 USD 2007-01-01 – 2007-12-31: 17747000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALBANY MOLECULAR RESEARCH INC · 2007-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Capital Expenditure: 17747000 USD Concept: fundies:CapitalExpenditure Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ACapitalExpenditure&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 17747000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/0001144204-10-013181.txt#16013 The citation records this snapshot. The page link may show a newer release later.	USD 13.92 million Calculation and evidence 31667000 − 17747000 USD Exact free cash flow: 13920000 USD 2007-01-01 – 2007-12-31: 31667000 USD · Inspect Operating Cash Flow · Source 2007-01-01 – 2007-12-31: 17747000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALBANY MOLECULAR RESEARCH INC · 2007-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Free cash flow: 13920000 USD Concept: free-cash-flow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 31667000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/0001144204-10-013181.txt#15907 Input fundies:CapitalExpenditure: 17747000 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/0001144204-10-013181.txt#16013 The citation records this snapshot. The page link may show a newer release later.
2008 2008-01-01 – 2008-12-31	USD 20.56 million Exact value Exact value: 20560000 USD 2008-01-01 – 2008-12-31: 20560000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALBANY MOLECULAR RESEARCH INC · 2008-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Net Income: 20560000 USD Concept: fundies:NetIncome Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ANetIncome&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:NetIncome: 20560000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/0001144204-11-015211.txt#12328 The citation records this snapshot. The page link may show a newer release later.	USD 26.54 million Exact value Exact value: 26540000 USD 2008-01-01 – 2008-12-31: 26540000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALBANY MOLECULAR RESEARCH INC · 2008-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Operating Cash Flow: 26540000 USD Concept: fundies:OperatingCashFlow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3AOperatingCashFlow&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 26540000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/0001144204-11-015211.txt#12680 The citation records this snapshot. The page link may show a newer release later.	USD 23.94 million Exact value Exact value: 23938000 USD 2008-01-01 – 2008-12-31: 23938000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALBANY MOLECULAR RESEARCH INC · 2008-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Capital Expenditure: 23938000 USD Concept: fundies:CapitalExpenditure Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ACapitalExpenditure&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 23938000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/0001144204-11-015211.txt#12760 The citation records this snapshot. The page link may show a newer release later.	USD 2.6 million Calculation and evidence 26540000 − 23938000 USD Exact free cash flow: 2602000 USD 2008-01-01 – 2008-12-31: 26540000 USD · Inspect Operating Cash Flow · Source 2008-01-01 – 2008-12-31: 23938000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALBANY MOLECULAR RESEARCH INC · 2008-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Free cash flow: 2602000 USD Concept: free-cash-flow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 26540000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/0001144204-11-015211.txt#12680 Input fundies:CapitalExpenditure: 23938000 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/0001144204-11-015211.txt#12760 The citation records this snapshot. The page link may show a newer release later.
2009 2009-01-01 – 2009-12-31	−USD 16.7 million Exact value Exact value: -16695000 USD 2009-01-01 – 2009-12-31: -16695000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALBANY MOLECULAR RESEARCH INC · 2009-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Net Income: -16695000 USD Concept: fundies:NetIncome Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ANetIncome&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:NetIncome: -16695000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420412015296/amri-20111231.xml#29456 Filing: 000114420412015296 The citation records this snapshot. The page link may show a newer release later.	USD 39.09 million Exact value Exact value: 39086000 USD 2009-01-01 – 2009-12-31: 39086000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALBANY MOLECULAR RESEARCH INC · 2009-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Operating Cash Flow: 39086000 USD Concept: fundies:OperatingCashFlow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3AOperatingCashFlow&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 39086000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420412015296/amri-20111231.xml#26824 Filing: 000114420412015296 The citation records this snapshot. The page link may show a newer release later.	USD 15.17 million Exact value Exact value: 15172000 USD 2009-01-01 – 2009-12-31: 15172000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALBANY MOLECULAR RESEARCH INC · 2009-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Capital Expenditure: 15172000 USD Concept: fundies:CapitalExpenditure Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ACapitalExpenditure&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 15172000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420412015296/amri-20111231.xml#30661 Filing: 000114420412015296 The citation records this snapshot. The page link may show a newer release later.	USD 23.91 million Calculation and evidence 39086000 − 15172000 USD Exact free cash flow: 23914000 USD 2009-01-01 – 2009-12-31: 39086000 USD · Inspect Operating Cash Flow · Source 2009-01-01 – 2009-12-31: 15172000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALBANY MOLECULAR RESEARCH INC · 2009-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Free cash flow: 23914000 USD Concept: free-cash-flow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 39086000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420412015296/amri-20111231.xml#26824 Filing: 000114420412015296 Input fundies:CapitalExpenditure: 15172000 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420412015296/amri-20111231.xml#30661 Filing: 000114420412015296 The citation records this snapshot. The page link may show a newer release later.
2010 2010-01-01 – 2010-12-31	−USD 62.87 million Exact value Exact value: -62871000 USD 2010-01-01 – 2010-12-31: -62871000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALBANY MOLECULAR RESEARCH INC · 2010-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Net Income: -62871000 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: -62871000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420413015765/amri-20121231.xml#524282 Filing: 000114420413015765 The citation records this snapshot. The page link may show a newer release later.	−USD 1.32 million Exact value Exact value: -1321000 USD 2010-01-01 – 2010-12-31: -1321000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALBANY MOLECULAR RESEARCH INC · 2010-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Operating Cash Flow: -1321000 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3AOperatingCashFlow&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1321000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420413015765/amri-20121231.xml#523642 Filing: 000114420413015765 The citation records this snapshot. The page link may show a newer release later.	USD 11.63 million Exact value Exact value: 11628000 USD 2010-01-01 – 2010-12-31: 11628000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALBANY MOLECULAR RESEARCH INC · 2010-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Capital Expenditure: 11628000 USD Concept: fundies:CapitalExpenditure Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ACapitalExpenditure&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11628000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420413015765/amri-20121231.xml#592574 Filing: 000114420413015765 The citation records this snapshot. The page link may show a newer release later.	−USD 12.95 million Calculation and evidence -1321000 − 11628000 USD Exact free cash flow: -12949000 USD 2010-01-01 – 2010-12-31: -1321000 USD · Inspect Operating Cash Flow · Source 2010-01-01 – 2010-12-31: 11628000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALBANY MOLECULAR RESEARCH INC · 2010-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Free cash flow: -12949000 USD Concept: free-cash-flow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1321000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420413015765/amri-20121231.xml#523642 Filing: 000114420413015765 Input fundies:CapitalExpenditure: 11628000 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420413015765/amri-20121231.xml#592574 Filing: 000114420413015765 The citation records this snapshot. The page link may show a newer release later.
2011 2011-01-01 – 2011-12-31	−USD 32.3 million Exact value Exact value: -32296000 USD 2011-01-01 – 2011-12-31: -32296000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALBANY MOLECULAR RESEARCH INC · 2011-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Net Income: -32296000 USD Concept: fundies:NetIncome Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ANetIncome&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:NetIncome: -32296000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420414016173/amri-20131231.xml#794954 Filing: 000114420414016173 The citation records this snapshot. The page link may show a newer release later.	−USD 1.48 million Exact value Exact value: -1481000 USD 2011-01-01 – 2011-12-31: -1481000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALBANY MOLECULAR RESEARCH INC · 2011-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Operating Cash Flow: -1481000 USD Concept: fundies:OperatingCashFlow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3AOperatingCashFlow&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -1481000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420414016173/amri-20131231.xml#1387290 Filing: 000114420414016173 The citation records this snapshot. The page link may show a newer release later.	USD 10.84 million Exact value Exact value: 10837000 USD 2011-01-01 – 2011-12-31: 10837000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALBANY MOLECULAR RESEARCH INC · 2011-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Capital Expenditure: 10837000 USD Concept: fundies:CapitalExpenditure Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ACapitalExpenditure&period=2011-12-31&surface=latest&period_type=duration&start=2011-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 10837000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420414016173/amri-20131231.xml#1840273 Filing: 000114420414016173 The citation records this snapshot. The page link may show a newer release later.	−USD 12.32 million Calculation and evidence -1481000 − 10837000 USD Exact free cash flow: -12318000 USD 2011-01-01 – 2011-12-31: -1481000 USD · Inspect Operating Cash Flow · Source 2011-01-01 – 2011-12-31: 10837000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALBANY MOLECULAR RESEARCH INC · 2011-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Free cash flow: -12318000 USD Concept: free-cash-flow Period: 2011-01-01 to 2011-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -1481000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420414016173/amri-20131231.xml#1387290 Filing: 000114420414016173 Input fundies:CapitalExpenditure: 10837000 USD (2011-01-01 to 2011-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420414016173/amri-20131231.xml#1840273 Filing: 000114420414016173 The citation records this snapshot. The page link may show a newer release later.
2012 2012-01-01 – 2012-12-31	−USD 4.26 million Exact value Exact value: -4261000 USD 2012-01-01 – 2012-12-31: -4261000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALBANY MOLECULAR RESEARCH INC · 2012-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Net Income: -4261000 USD Concept: fundies:NetIncome Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ANetIncome&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:NetIncome: -4261000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420415016363/amri-20141231.xml#636094 Filing: 000114420415016363 The citation records this snapshot. The page link may show a newer release later.	USD 15.34 million Exact value Exact value: 15337000 USD 2012-01-01 – 2012-12-31: 15337000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALBANY MOLECULAR RESEARCH INC · 2012-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Operating Cash Flow: 15337000 USD Concept: fundies:OperatingCashFlow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3AOperatingCashFlow&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 15337000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420415016363/amri-20141231.xml#1356732 Filing: 000114420415016363 The citation records this snapshot. The page link may show a newer release later.	USD 9.89 million Exact value Exact value: 9890000 USD 2012-01-01 – 2012-12-31: 9890000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALBANY MOLECULAR RESEARCH INC · 2012-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Capital Expenditure: 9890000 USD Concept: fundies:CapitalExpenditure Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ACapitalExpenditure&period=2012-12-31&surface=latest&period_type=duration&start=2012-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 9890000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420415016363/amri-20141231.xml#1357918 Filing: 000114420415016363 The citation records this snapshot. The page link may show a newer release later.	USD 5.45 million Calculation and evidence 15337000 − 9890000 USD Exact free cash flow: 5447000 USD 2012-01-01 – 2012-12-31: 15337000 USD · Inspect Operating Cash Flow · Source 2012-01-01 – 2012-12-31: 9890000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALBANY MOLECULAR RESEARCH INC · 2012-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Free cash flow: 5447000 USD Concept: free-cash-flow Period: 2012-01-01 to 2012-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 15337000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420415016363/amri-20141231.xml#1356732 Filing: 000114420415016363 Input fundies:CapitalExpenditure: 9890000 USD (2012-01-01 to 2012-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420415016363/amri-20141231.xml#1357918 Filing: 000114420415016363 The citation records this snapshot. The page link may show a newer release later.
2013 2013-01-01 – 2013-12-31	USD 11.77 million Exact value Exact value: 11768000 USD 2013-01-01 – 2013-12-31: 11768000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALBANY MOLECULAR RESEARCH INC · 2013-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Net Income: 11768000 USD Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:NetIncome: 11768000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420416091051/amri-20151231.xml#270661 Filing: 000114420416091051 The citation records this snapshot. The page link may show a newer release later.	USD 28.18 million Exact value Exact value: 28176000 USD 2013-01-01 – 2013-12-31: 28176000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALBANY MOLECULAR RESEARCH INC · 2013-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Operating Cash Flow: 28176000 USD Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 28176000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420416091051/amri-20151231.xml#287840 Filing: 000114420416091051 The citation records this snapshot. The page link may show a newer release later.	USD 11.14 million Exact value Exact value: 11135000 USD 2013-01-01 – 2013-12-31: 11135000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALBANY MOLECULAR RESEARCH INC · 2013-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Capital Expenditure: 11135000 USD Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11135000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420416091051/amri-20151231.xml#288233 Filing: 000114420416091051 The citation records this snapshot. The page link may show a newer release later.	USD 17.04 million Calculation and evidence 28176000 − 11135000 USD Exact free cash flow: 17041000 USD 2013-01-01 – 2013-12-31: 28176000 USD · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 11135000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALBANY MOLECULAR RESEARCH INC · 2013-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Free cash flow: 17041000 USD Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 28176000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420416091051/amri-20151231.xml#287840 Filing: 000114420416091051 Input fundies:CapitalExpenditure: 11135000 USD (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420416091051/amri-20151231.xml#288233 Filing: 000114420416091051 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−USD 3.28 million Exact value Exact value: -3278000 USD 2014-01-01 – 2014-12-31: -3278000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALBANY MOLECULAR RESEARCH INC · 2014-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Net Income: -3278000 USD Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:NetIncome: -3278000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#323027 Filing: 000114420417015129 The citation records this snapshot. The page link may show a newer release later.	USD 1.91 million Exact value Exact value: 1905000 USD 2014-01-01 – 2014-12-31: 1905000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALBANY MOLECULAR RESEARCH INC · 2014-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Operating Cash Flow: 1905000 USD Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 1905000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1795147 Filing: 000114420417015129 The citation records this snapshot. The page link may show a newer release later.	USD 17.19 million Exact value Exact value: 17189000 USD 2014-01-01 – 2014-12-31: 17189000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALBANY MOLECULAR RESEARCH INC · 2014-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Capital Expenditure: 17189000 USD Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 17189000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1796395 Filing: 000114420417015129 The citation records this snapshot. The page link may show a newer release later.	−USD 15.28 million Calculation and evidence 1905000 − 17189000 USD Exact free cash flow: -15284000 USD 2014-01-01 – 2014-12-31: 1905000 USD · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 17189000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALBANY MOLECULAR RESEARCH INC · 2014-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Free cash flow: -15284000 USD Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 1905000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1795147 Filing: 000114420417015129 Input fundies:CapitalExpenditure: 17189000 USD (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1796395 Filing: 000114420417015129 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−USD 2.3 million Exact value Exact value: -2301000 USD 2015-01-01 – 2015-12-31: -2301000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALBANY MOLECULAR RESEARCH INC · 2015-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Net Income: -2301000 USD Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:NetIncome: -2301000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#319162 Filing: 000114420417015129 The citation records this snapshot. The page link may show a newer release later.	USD 39.63 million Exact value Exact value: 39628000 USD 2015-01-01 – 2015-12-31: 39628000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALBANY MOLECULAR RESEARCH INC · 2015-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Operating Cash Flow: 39628000 USD Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 39628000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1794908 Filing: 000114420417015129 The citation records this snapshot. The page link may show a newer release later.	USD 22.04 million Exact value Exact value: 22041000 USD 2015-01-01 – 2015-12-31: 22041000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALBANY MOLECULAR RESEARCH INC · 2015-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Capital Expenditure: 22041000 USD Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 22041000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1796196 Filing: 000114420417015129 The citation records this snapshot. The page link may show a newer release later.	USD 17.59 million Calculation and evidence 39628000 − 22041000 USD Exact free cash flow: 17587000 USD 2015-01-01 – 2015-12-31: 39628000 USD · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 22041000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALBANY MOLECULAR RESEARCH INC · 2015-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Free cash flow: 17587000 USD Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 39628000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1794908 Filing: 000114420417015129 Input fundies:CapitalExpenditure: 22041000 USD (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1796196 Filing: 000114420417015129 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−USD 70.17 million Exact value Exact value: -70171000 USD 2016-01-01 – 2016-12-31: -70171000 USD Inspect Net Income Open source Share or cite Citation for Net Income · ALBANY MOLECULAR RESEARCH INC · 2016-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Net Income: -70171000 USD Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:NetIncome: -70171000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#319022 Filing: 000114420417015129 The citation records this snapshot. The page link may show a newer release later.	USD 26.64 million Exact value Exact value: 26635000 USD 2016-01-01 – 2016-12-31: 26635000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ALBANY MOLECULAR RESEARCH INC · 2016-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Operating Cash Flow: 26635000 USD Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 26635000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1794669 Filing: 000114420417015129 The citation records this snapshot. The page link may show a newer release later.	USD 51.43 million Exact value Exact value: 51428000 USD 2016-01-01 – 2016-12-31: 51428000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ALBANY MOLECULAR RESEARCH INC · 2016-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Capital Expenditure: 51428000 USD Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 51428000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1795997 Filing: 000114420417015129 The citation records this snapshot. The page link may show a newer release later.	−USD 24.79 million Calculation and evidence 26635000 − 51428000 USD Exact free cash flow: -24793000 USD 2016-01-01 – 2016-12-31: 26635000 USD · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 51428000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ALBANY MOLECULAR RESEARCH INC · 2016-12-31 ALBANY MOLECULAR RESEARCH INC (edgar:1065087) Free cash flow: -24793000 USD Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T17:12:30Z Snapshot: 290efa3a1abdd86bb9a140497d6b6ec886a8cf971af7e8046cfc316fdf5dee01 Dimensions: Consolidated View: https://fundies.io/companies/edgar/1065087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 26635000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1794669 Filing: 000114420417015129 Input fundies:CapitalExpenditure: 51428000 USD (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1065087/000114420417015129/amri-20161231.xml#1795997 Filing: 000114420417015129 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

211 filings · 2,621 latest values · 2,621 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001065087, 1065087, AMRI, edgar:1065087

Also known as ALBANY MOLECULAR RESEARCH INC

ALBANY MOLECULAR RESEARCH INC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Free cash flow

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2016 2016-01-01 – 2016-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation